FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

illigion, D.C. 20049	OMB APPROVAL

l	OMB Number:	3235-0287
l	Estimated average bure	den
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* GOLDSTEIN DOV A MD					2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA]							(Ch	neck all appli X Directo	or	10% Ov	vner	
888 SEVENTH AVE					3. Date of Earliest Transaction (Month/Day/Year) 01/30/2015								Officer below	(give title	Other (s below)	specify	
30TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) NEW YO	ORK N	Y	10106							- 1	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transact Date (Month/Date)				Execution Date		Code (I	Transaction Code (Instr. 5) Disposed Of (D) (Instr. 3, 5)			tr. 3, 4 and	Benefici Owned Reporte Transac	es Fo ially (D Following d tion(s)	orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares					
Options to purchase	\$10.8 ⁽¹⁾	01/30/2015		A		9,000		(2)	01	1/30/2025	Common Stock	9,000	\$0	9,000	D ⁽³⁾		

- 1. The exercise price reflects the per share fair market value of the Company's common stock, as determined by the closing price of the Company's common stock on the NASADAQ Stock Market on January 30, 2015, the date that the option grant was approved by the Company's board of directors.
- 2. These options will vest monthly over a period of 24 months and terminate 12 months following separation.
- 3. These stock options are held by Dr. Goldstein for the benefit of Aisling Capital LLC. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

02/03/2015 /s/ Dov A. Goldstein

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.